ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $77.33.

ANIP has been the subject of a number of recent analyst reports. Truist Financial upped their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research note on Tuesday, October 22nd. Raymond James upped their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research note on Wednesday, September 18th. StockNews.com downgraded ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. HC Wainwright reiterated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Finally, Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an "overweight" rating and a $68.00 price target for the company.

ANI Pharmaceuticals Stock Up 0.6 %

Shares of ANIP traded up $0.35 during trading hours on Thursday, reaching $58.75. 53,301 shares of the stock traded hands, compared to its average volume of 213,544. The company has a market cap of $1.24 billion, a price-to-earnings ratio of 49.91 and a beta of 0.71. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $58.78 and a 200 day simple moving average of $61.60. ANI Pharmaceuticals has a 52 week low of $48.20 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.95 by $0.07. The firm had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business's revenue for the quarter was up 18.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 EPS. On average, equities analysts forecast that ANI Pharmaceuticals will post 3.51 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ANIP. Vanguard Group Inc. increased its stake in ANI Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company's stock worth $90,314,000 after acquiring an additional 17,460 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in ANI Pharmaceuticals by 3.5% in the second quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company's stock valued at $40,132,000 after purchasing an additional 21,053 shares in the last quarter. Millennium Management LLC lifted its position in ANI Pharmaceuticals by 1,005.8% during the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock valued at $14,651,000 after purchasing an additional 209,272 shares during the last quarter. Thompson Siegel & Walmsley LLC grew its stake in ANI Pharmaceuticals by 1.5% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 195,743 shares of the specialty pharmaceutical company's stock worth $12,465,000 after buying an additional 2,986 shares in the last quarter. Finally, Mizuho Markets Americas LLC purchased a new position in ANI Pharmaceuticals in the 3rd quarter worth approximately $11,670,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.